TriangleNCT02004522 · OUTCOME
Duration of Response (DOR)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from the first documentation of response to first documentation of progressive disease or death due to any cause
What was measured
Duration of response is defined only for subjects demonstrating a response (eg, CR, CRi, PR, PRwL), with the response and progression statuses both determined by the blinded, central independent review. The analysis will be descriptive for each treatment group only.
Analysis population: Intent to Treat
Groups in this outcome
Duvelisib
Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
Ofatumumab
Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.
| Group | Source count |
|---|---|
| Duvelisib | 160 |
| Ofatumumab | 159 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Duvelisib | 11.1 | Not reported | 9.2 | 18.3 | Not reported |
| Ofatumumab | 9.3 | Not reported | 7.7 | 11.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9.2
- upper Limit
- 18.3
- value
- 11.1
- group Id
- OG001
- lower Limit
- 7.7
- upper Limit
- 11.0
- value
- 9.3
- denoms
- counts
- group Id
- OG000
- value
- 160
- group Id
- OG001
- value
- 159
- units
- Participants
- description
- Duration of response is defined only for subjects demonstrating a response (eg, CR, CRi, PR, PRwL), with the response and progression statuses both determined by the blinded, central independent review. The analysis will be descriptive for each treatment group only.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.
- id
- OG000
- title
- Duvelisib
- description
- Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.
- id
- OG001
- title
- Ofatumumab
- param Type
- MEDIAN
- population Description
- Intent to Treat
- reporting Status
- POSTED
- time Frame
- Time from the first documentation of response to first documentation of progressive disease or death due to any cause
- title
- Duration of Response (DOR)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice